Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin.

Front Immunol · 2025 · PMC11807999 · PMID 39931058

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantp=0.052so close (0.05 < p ≤ 0.1)

However, there was a borderline significant higher incidence of HLA mismatch in the ATG-T group compared to the ATG-F group (39.1% Vs. 21.2%; p=0.052, Chi-Square test).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.